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Exhaled nitric oxide partitioned into alveolar,
lower airways and nasal contributions
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During the last year exhaled nitric oxide (NO) has been proposed as a marker of airway inflammation. More
knowledge of the production and transfer of this molecule are needed in order for NO analysis to become a clinical
tool. This was the aim of the study.
Exhaled NO values from multiple flow rates were used to model alveolar NO, transfer rate and tissue
concentration of NO in the airways. Three flows rates, 0?005, 0?1 and 0?5 l sec71 were found to be optimal. The NO
transfer rate of the airways was 9+2ml sec71, the tissue source was 75+28 ppb and the alveolar fraction of NO
was 2+1 ppb in 10 healthy subjects (mean+CI95%).
In conclusion, we have shown that it is possible to get more information about the distribution of NO in the
lungs and the airways than only a single value from one expiratory flow rate can give. Further studies will reveal if
this airway modelling can be useful in disease of the respiratory system.
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During the past few years, the interest in monitoring
exhaled nitric oxide (NO) has been increasing dramatically
after it was proposed as a promising non-invasive tool in
the diagnosis of asthma and other airway inflammatory
disease. Early studies showed elevated fractions of NO
(FENO) in subjects with asthma (1,2). After more under-
standing had been achieved about the strong flow
dependency of exhaled NO (3,4), as well as the techniques
to separate the contributions from the nasal cavity and
lower airways (3,5), it became evident that the results
presented so far may not be comparable. The need to
standardize the measurement procedures was realized and a
recommendation of The European Respiratory Society
Task Force on ‘Measurements of nitric oxide in exhaled air’
was published (6). The more recent research complying with
the recommended measurement procedures has already
been starting to show results that are contradictory (7). This
seems to indicate that the link between NO output and lung
or airway disease is much more complex than expected
(8,9).
Exogenous inhaled NO selectively dilates pulmonary
vessels in ventilated lung regions. In this way ventilation–
perfusion matching can be modulated to improve oxygena-Received 3 May 1999 and accepted in revised form 1 May 2000.
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0954-6111/00/100985+07 $35?00/0tion and lower pulmonary artery pressure in patients with
hypoxaemia (10,11) and pulmonary hypertension (12,13).
The NO contribution from the nose, and especially the
sinus cavities, has been shown to be high (14). Therefore,
not only exogenous NO but also endogenous NO may
increase oxygenation of the blood. It has been reported that
there was an increase in oxygen tension during nose
breathing compared to mouth breathing (15). We therefore
feel that appropriate attention should be given to the role of
NO from the nose cavity during normal breathing when
searching for the potential diagnostic value of the NO
measurements. In this paper we want to present a novel
approach for the measurement and the calculation of the
NO derived in the nasal cavity utilizing simple procedures
complementary to and in compliance with the ones
recommended for the measurements of exhaled NO from
the lower airways.
We also want to demonstrate that it is possible to utilize a
simplified diffusion based modelling for the NO output to
the airways during oral breathing during constant flow
manoeuvres. For the basis of the experimental work we
wanted to revisit the issue of the inhalation manoeuvre
preceding the exhalation measurements. Inspiration to total
lung capacity (TLC) is the recommended breathing
manoeuvre, i.e. vital capacity (VC) manoeuvre, for attain-
ing the plateau concentration of FENO (6). This manoeuvre
is dicult to achieve for subgroups of patients such as small
children, patients with severe lung disease and in the
elderly. In addition, repeated spirometry in asthmatics
results in reduced FENO (16). We therefore compared the
FENO from the VC manoeuvre with that of a deep
inhalation, which is easier to perform.# 2000 HARCOURT PUBLISHERS LTD
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EXPERIMENTS
Study population
Healthy volunteers (n=52, 27 men and 25 women) were
included in this study. They were non-smokers, and none
had had a history of respiratory infection during the
previous month or any allergic symptoms. In addition,
subjects with a diagnosis of asthma (n=5, two men and
three women) treated with inhaled steroids and smokers
(n=5, all women) with no history of respiratory infection
during the previous month were investigated. All subjects
were told not to eat or drink 2 h before the study occasion.
Analysing equipment
NO and end tidal CO2 concentrations, flow rate and airway
pressure were measured with a computer-based single-
breath NO system from Nitrograf AB, Ha¨sselby, Sweden.
Included in this system are a Sievers NOA 280 chemilumi-
nescence analyser (Sievers, Boulder, CO, U.S.A.) and an
infrared CO2 analyser. The sampling rate of the NO system
was adjusted to 200mlmin71. The repeatability of the
system was 5 1 ppb with a response time of 5200msec.
The system was calibrated using a mixture of 460 ppb NO
in nitrogen (AGA AB, Lidingo¨, Sweden) and the zero was
set by feeding synthetic air (AGA AB) into a 2 l canister
filled with Purafil II chemisorbant with purakol (Lindair
AB, Ljusne, Sweden). Care was taken that the sampling
flow of the analysing probe was kept the same as the flow at
which the system was calibrated. A flow indicator was
therefore attached to the system and the sampling flow was
controlled before and after each measurement. The
temperature of the photomultiplier tube of the analyser
differed less than 18C from the temperature at which the
calibration was performed. Since the NO signal is
expiratory flow dependent (3,4) the NO system also
includes measurements of expiratory flow rate. The flow
sensor, D-liteTM (Datex-Ohmeda, Helsinki, Finland) was
calibrated in the range of 0–0?5 l sec71 (Dry Cal DC-2 flow
calibrator, BIOS International, Pompton Plains, NJ,
U.S.A.) Controls of calibration and flow rate of the
sampling system were done daily and the zero was
controlled before each measurement.
The subjects were instructed to perform a deep inhala-
tion, except in protocol (a), and exhale with a constant flow.
To facilitate for the volunteers to keep a constant
expiratory flow, a resistance (Model #7100R 20, Hans
Rudolph, Inc., Kansas City, MO, U.S.A.) was fitted onto
the expiratory side of the two-way, non-rebreathing valve
(Model 1410, Hans Rudolph). The expiratory pressure was
5 cmH2O or above, but always less than 20 cmH2O, to
exclude NO from the nose cavity (3,5). Some volunteers
needed increased resistance to be able to keep a constant
expiratory flow and in these cases a higher resistance was
used (Model #7100R 50, Hans Rudolph). The expiratory
pressure has been shown not to influence the NOconcentrations (3,4). The NO value was taken when there
was a steady plateau longer than 3 sec. A mean value of
three breaths was used for statistical analysis. The
concentration of NO is expressed as FENO in ppb and the
volume of exhaled NO is expressed as VENO in nlmin
71.
VENOwas calculated by multiplying the FENO plateau values
with the expiratory flow rate.
Experimental procedure
(a) In six subjects the recommended procedure to measure
exhaled NO (6), i.e. after a VC-manoeuvre, was
compared to a deep inhalation. After each VC-
manoeuvre the subject rested 430 sec but 51min.
The exhalation flow rate was 0?1 l sec71. The time to
achieve a plateau and the plateau value of exhaled NO
was determined for the two different procedures.
(b) To establish the contribution of NO from the
nasopharynx in relation to the exhaled NO from the
tracheobronchial tree, FENO was investigated in 10
female and 10 male healthy subjects. FENO was
measured at five different expiratory flow rates in the
range of 0?05–0?32 l sec71 during mouth breathing
and nose breathing into mask covering the nose
(CPAP mask S, Resperonic, Medela Medical AB,
Ta¨by, Sweden).
(c) In another eight healthy volunteers we tested whether
it was possible to isolate the NO contribution from the
nose. NO was measured in the pharynx at an
inspiratory and expiratory flow rate of 0?115 l sec71
during nasal breathing. NO was sampled in the
pharynx using an artificial airway no. 2 or 3 (Portex,
Nerck-sur-Mer, France) where a channel had been
made for the connection of the NO probe. To compare
these values with NO levels during nasal exhalation
and mouth exhalation we can utilize the requirement
of the mass balance. The measured NO output from
nasal exhalation needs to equal the sum of the NO
output from the mouth and the net NO output from
the nasal cavity. The output equals the flow multiplied
by the concentration, and since the flow remaining the
same on both sides of the equation it is cancelled out:
FENO -nose ¼ FENO-mouthþ FNO-nose
By rearranging this for the net NO concentration that
the nose adds to exhalation
FNO-nose ¼ FENO-noseÿ FENO-mouth ðiÞ
The same procedure as applied to inhalation combines
the NO content inhaled and the net output from the
nasal cavity to the NO content measured at the
pharynx as follows:
FINO -nose ¼FINO -pharynxÿ
FNO-ambient air
ðiiÞ
The range of ambient NO concentrations during these
measurements were 0?272?4 ppb.
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is based on Fick’s law of diffusion, we computed the
alveolar fraction of NO (FANO), the tissue source of
NO (FwNOÞ and the airway transfer rate of NO (DwNOÞ
in 10 subjects. We used 11 flow rates between
0?00570?5 l sec71 for the least square fitting. We
also calculated the FANO from the equation (10) and
then used the 11 flow rates to calculate FwNO and
DwNO . In addition, we used the same procedure but
limited the flow rates to 0?005, 0?01 and 0?5 l sec71.
THEORY
Modelling of the lower airways
The entire tracheobronchial tree is assumed to be lumped
into a single cylindrical tube with a constant inner radius (r)
and length (L). A barrier layer of thickness (d) covers the
inner wall of the airway lumen. The NO is generated in, and
temporarily stored by, the lumped single tissue layer and
diffused through an aqueous barrier to the airway lumen. A
portion of the generated NO will be diffused to the opposite
direction and scavenged by the blood circulating in the
tissue.
The gas enters the tube at constant volume flow ( _Q) and
has a NO concentration of FinNO . Let’s assume that the
Fick’s law of diffusion controls the radial transfer rate of
the NO from the source layer through the barrier layer:
_JNO ¼ kAe
d
 ðFwNO ÿ FNOðxÞÞ ð1Þ
where _JNO is the volumetric transfer rate of NO, k the
diffusion coecient of NO in the barrier layer, d the
thickness of the layer and Ae the area of the excreting
surface element. The concentration equivalent to the partial
pressure of NO in the wall source layer is FwNO and its value
in the airway lumen at the distance of x from the entrance is
FNOðxÞ We exclude in this context the issue of how FwNO ,
the NO generation rate in the tissue layer, and the NO flux
to the bronchial circulation are related to each other. We
neglect the axial diffusion along the airway lumen and
assume the radial mixing to be perfect.
We formulate a different equation to describe the
accumulation of NO. Let the leading front of the flow
propagate along the tube a distance (dx) in a time (dt) and
look at the amount of NO excreted into an infinitesimal
cylinder element of the volume dV ¼ r2 dx:
dFNO ¼ FNOðxþ dxÞ ÿ FNOðxÞ ¼
_JNOdt
dV
¼
_JNO
_Q
ð2Þ
Combining this with (1) gives
dFNO ¼ 2rk  dx_Q  d ðFWNO ÿ FNOðxÞÞ ð3Þ
This makes a differential equation:
dFNO
dx
¼ 2rk
_Q  d ðFWNO ÿ FNOðxÞÞ ð4ÞThe solution for the boundary condition FNOð0Þ ¼ FinNO is
FNOðxÞ ¼ FWNO ÿ ðFWNO ÿ FinNOÞeÿ
2rkx
_Qd ð5Þ
Then the exhaled NO concentration FoutNO at the exit of the
tube at x ¼ L is
FoutNO ¼ FNOðLÞ ¼ FWNO ÿ ðFWNO ÿ FinNOÞeÿ
2rkL
_Qd ð6Þ
Introducing a diffusion rate constant DWNO ¼ 2rkL=d
¼ Ak=d where A is the surface area of the cylinder, results
to the final formula
FoutNO ¼ FNOðLÞ ¼ FWNO ÿ ðFWNO ÿ FinNOÞeÿ
DWNO
_Q
¼ FinNOeÿ
DWNO
_Q þ FwNOð1ÿ e
ÿDWNO
_Q Þ ð7Þ
The model opens a possibility to identify the alveolar NO
concentration (FANO ¼ FinNOÞ, the tissue source NO concen-
tration (FWNOÞ and the airway NO transfer rate (DWNO ) by
applying the least square fitting method upon the exhaled
oral NO profile data measured at controlled conditions.
NO output from the lower airways
The rate of the NO volume released from a compartment
( _VNO) is defined as NO output and is obtained by
multiplying the concentration by flow:
_VENO ¼ FoutNO  _Q ð8Þ
_VENO ¼ ðFinNOe
ÿDWNO
_Q þ FwNOð1ÿ e
ÿDWNO
_Q ÞÞ  _Q ð9Þ
At high enough flows of _Q (when _Q >> DwNOÞ; eÿDWNO= _Q
¼ 1ÿDWNO= _Q; and (9) can be written as;
_VENO ¼ ðFwNO ÿ FinNOÞDwNO þ FinNO _Q ð10Þ
This equation represents a straight line with a slope of FinNO
and offers an alternative way to determine the alveolar NO
concentration if enough data points of _VNO vs: _Q are
measured at high flows to find the slope of the line. This
approach was also suggested by Tsoukias et al. (17).
STATISTICAL ANALYSIS
The t-test for paired samples and ANOVA for repeated
measurements were used to compare data within the groups
at different flow rates. The Tukey honest significant
difference test was used for post hoc comparisons and
probability values were calculated. For correlation the
Spearman rank correlation coecient was used. For all
statistical calculations the Statistica/w 5.0 software package
(StatSoft Inc., Tulsa, OK, U.S.A.) was used. Results are
given as mean values and +95% confidence interval
(CI95%) in text, tables and figures.
Results
The subjects all performed well and the expiratory flow
rates in the different protocols were less than+10% of the
target flow.
FIG. 2. Correlation between calculated NO and measured
value obtained during inspiration and expiration. There
was a good agreement between the FINO measured in the
pharynx, with the ambient NO concentration subtracted,
and that of the FNO-nose where the FENO-mouth values
had been subtracted (r=0?98, P50?001).
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in a FENO 0.1 of 12?1+4?7 ppb. The time to reach a plateau
after a VC manoeuvre was 16?4+3?7 sec. The correspond-
ing values after a deep breath were 12?4+4?7 ppb and
7?7+2?7 sec. There was no statistical difference in FENO
between the manoeuvres, but the time to reach a plateau
was significantly longer (P50?01) for the VC manoeuvre.
In protocol (b) the FENO 0?25 was 4?2+1?2 ppb and FENO 0?1
was 8?3+2?5 ppb. There was no difference between the
exhaled NO in regards to gender and no correlation to age,
height or body weight. During mouth breathing, the FENO
was dependent of the expiratory flow (r=70?59,
P50?001). To obtain the nasopharyngeal contribution to
the expired plateau value the mouth values have to be
subtracted according to equation (i). The calculated FNO-
nose values from the nasopharynx were also flow depen-
dent, r=70?71, P50?001. The VENO-mouth and VNO-nose
was significantly different for different flow rates
(P50?001). (Fig. 1). There was also a significant difference
between the VENO and the VNO-nose (P5 0?001). The VNO-
nose was 4?4–4?9 times higher than that from the tracheo-
bronchial tree at the tested flow rates 0?0570?32 l sec71.
There was no statistically significant difference (P=0?75)
between the ratios measured at these flows.
In protocol (c) the measurements of NO obtained in the
pharynx were used for calculations of the net NO from the
nasal cavity. Applying the equations (i) and (ii) resulted
in a FINO-nose of 36?6+15?7 ppb and FNO-nose of
36?3+16?0 ppb. These values were not significantly differ-
ent and showed a good correlation, r=0?98 (P50?001)
(Fig. 2). Hence, there was no difference between exhaled
and inhaled fractions of NO from the nose cavity at the
measured flow rate. We also looked at the difference
between the plateau values of the FENO-mouth and the FENO-
pharynx since it has been proposed that the mouth cavity
contributes to the exhaled NO concentration (18). We
found no statistical difference between them, FENO-mouthFIG. 1. The VENO from the nasal cavity (upper curve) was
about five times higher than the VENO from the
tracheobronchial tree (lower curve, P50?001). The NO
output from both the nasal cavity and the
tracheobronchial tree changed with expiratory flow
(P50?001). For calculations of the different VENO, see
Method. Data are shown in mean values and CI95%
(dotted line).
FIG. 3. The importance of the expiratory flow rate in
discriminating between patient’s FENO values. The NO
profile, i.e. the expiratory flow dependence is nearly lost in
smokers (n=5, 6–15 cigarettes per day, ~). A clear
increase in FENO when exhaling at low flow rates is seen in
asthmatic patients treated with inhaled corticosteroids
(n=5, 400 7800 mg per day, &). For reference the FENO
values for control subjects in protocol (d) are shown
(n=10, *).was 11?6+8?1 ppb and the FENO-pharynx was
10?2+6?1 ppb (ns).
The 10 subjects used for modelling NO from the airways
in protocol (d) had a FENO 0?1 of 7?8+2?4 ppb (Fig. 3). Using
the equation (10) for calculation the FANO, the FwNO and the
DwNO showed no difference whether it was calculated with
eleven flow rates or just three flow rates (Table 1). However,
sample variance of the FANO determined by all 11 flow rates
was 0?8 and the sample variance of the calculated FANO
TABLE 1. The computed values, from ten subjects, of the alveolar fraction of NO (FANO), the fraction of NO in the airway wall
(FwNO) and the airway wall transfer rate of NO (DwNO)
Expiratory flow rates 0?005–0?5 l sec71 0?005, 0?1 and 0?5 sec71
Calculated*
FANO
Calculated{
FANO
FANO ppb 1?5+0?8 1?6+0?3 1?6+0?3 1?6+0?3
FwNO ppb 78?4+26?7 76?5+27?6 75?1+27?6 75?2+27?4
DwNO ml sec
71 8?6+2?7 8?7+2?3 9?2+1?9 9?1+1?8
Eleven different expiratory flow rates were compared with only three of these flow rates. Data are given in mean values and
+CI95%.
*The slope representing the FANO calculated by fitting from equation (10) after Tsoukias et al. (17).
{The slope representing the FANO calculated by subtracting the VENO 0?1 from VENO 0?5 and dividing the sum by the difference in
flow rate.
EXHALED NITRIC OXIDE 989from the NO slope as described by Tsoukias et al. (17) was
0?3. When using only three flow rates the sample variance
was decreased to 0?3. Using the flow rates 0?1 and
0?5 l sec71 one can easily compute the slope by substracting
the VENO 0?1 form VENO 0?5 and dividing the sum by the
difference in flow rate, as done in Table 1.
Discussion
We have shown in this study: (i) that extended information
can be retrieved from an exhaled NO analysis when three
different expiratory flows are used. (ii) There is no need for
the use of a VC manoeuvre in order to obtain a reliable NO
value. (iii) Inspired NO values from the nose can be
estimated from expired values. (iv) The NO output from
the nose during exhalation is about five times higher than
the NO output from the mouth.
In trying to understand what the exhaled NO value
means and the use of it in diagnosis and treatment of lung
disease, we used the Fick’s law of diffusion to calculate the
alveolar NO, the tissue source and the transfer rate of NO.
Using the equations in the method section we were able to
compute FANO, FwNO and DwNO as shown in Table 1. A
step forward was that the numerous flow rates could
be minimized to only three. We think that it is quite
acceptable to let the patient exhale at three different flow
rates in order to gather the information of FANO, FwNO and
DwNO. A lot of information about the patient’s NO from the
airways can be obtained if also the values from nose can be
measured and calculated in a similar way. These measure-
ments can easily be performed and the future will tell if they
are of any use in lung function testing and monitoring of
lung disease.
It is of considerable importance to use the appropriate
expiratory flow rates to be able to show significant
difference between different patient groups. An illustration
of this can be seen in Fig. 3. The mean values for smokers
(n=5) and subjects with asthma (n=5) are shown incomparison to the control group used for the diffusion
measurements in protocol (d). The difference becomes
greater the lower the expiratory flow. Laws of diffusion
control the output of NO from the airways as explained in
the theoretical part in the method. At high flows, when the
contact time of the alveolar or peripheral gas with the
airway surface is short, the peripheral NO concentration
dominates. Then, to demonstrate the NO output from the
airway wall, low flow rates may preferably be used to allow
time for diffusion. The most likely explanation for the
contradictory NO values obtained by Ho et al. in patients
with bronchiectasis (7) is that a higher expiratory flow rate
was used. Since it has been shown that patients with
bronchiectasis have a strong expression of inducible NO
synthase in the bronchial epithelium (19) one would expect
to find increased levels of exhaled NO. Elevated levels of
NO have also been found, when the NO measurements
were done during a very slow vital capacity manoeuvre in
this group of patients (20). This difference is most likely
caused by the different expiratory flow rates. The same can
be said for the studies of NO in patient with cystic fibrosis
where both normal (21,22) and reduced values have been
published (19). These patients have a very flat NO profile,
i.e. at low expiratory flow rates the FENO is low (unpublished
observation). Thus, using high flow rates no difference can
be seen from control subjects but at very low flow rates a
clear difference can be observed.
There was no difference in FENO whether an inspiration to
TLC was performed before the exhalation or just a deep
breath. The difference is in the longer exhalation time
necessary to achieve a steady NO plateau during exhala-
tion. Thus, it is important to wait until a plateau is achieved
after a VC manoeuvre, and that no down sloping value
should be accepted. A reliable NO value can be obtained
even though the patient is unable to perform a VC
manoeuvre. When repeated measurements in a research
situation are needed it is of importance not to perform
repeated VC manoeuvres sinces the FENO is known to
decrease after lung function measurements (16).
990 M. HO¨GMAN ET AL.It has been shown that an increase in oxygen tension
occurs during nose breathing compared to mouth breathing
(15). This points out the importance of measurements of the
amount of endogenous inhaled NO. Our results indicate
that it is possible to calculate the fraction of NO that is
inhaled through the nose from the exhaled values. The
optimal NO delivery to improve oxygen tension should
produce a high alveolar fraction of NO. This is best
achieved by a high delivery at the beginning of the
inspiration in order to reach the best ventilated areas.
During the respiratory pause NO is accumulated in the
nose and a high fraction is inhaled in the beginning of the
breath. If the inhaled NO fraction versus flow is known, it
would be possible to calculate the amount of the NO per
breath reaching the lung during any type of a flow pattern.
By measuring the exhaled NO by the same principle for
mouth and nose values one can calculate the ratio between
them. This ratio between the output from the nasal cavity
and the lower airways did not depend on flow. On the other
hand the nasal NO output as such was flow dependent in
the flow range we covered. Previous studies performed by
the nasal aspiration method have demonstrated that the
nasal NO output varies with flow in the flow range of 0?7 to
2?7 lmin71 (23), but not in the range of 0?2 to 0?7 lmin71
(24). The role of the turbulences generated by nasal
aerodynamics compared to the change of the diffusion
properties at different flows requires further attention to
understand the NO release mechanism in the nose. We
measured NO during inhalation from the nose inside the
pharynx only at one flow rate, so it is not excluded that
different NO output mechanisms may be involved at
essentially smaller or higher inhalation flows than our
0?1 l sec71. A systematic comparison of the nasal NO
concentration and output in the serial vs. parallel measure-
ment configuration would be helpful in this context.
Inhalation of exogenous NO, as in smoking, causes the
FENO to decrease as shown in Fig. 3. Whether a compen-
satory increase in NO production occurs in the nose cavity
and causes a shift in the ratio we do not currently know.
In conclusion, for patients that cannot co-operate to
perform a VC-manoeuvre or in studies that need repeated
measurements an exhalation after a deep inhalation can
give an accurate NO value. Using a diffusion model we
were able to compute alveolar NO fraction, airway transfer
rate, and airway tissue source of NO. Clinical investigations
are now needed to show the usefulness of these calculations
in the diagnosis and treatment of respiratory diseases.
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